Non-canonical NF-kB and inflammation in diabetic kidney disease
Official title: Non-canonical NF-kB signaling in diabetic kidney disease
Funded at University of Hawaii at Manoa · NIH-11372089 · Data updated 2026-11-12
A study to understand how a specific inflammatory pathway worsens kidney disease in adults with type 2 diabetes and how it might be treated.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Hawaii at Manoa NIH-funded |
| Lab location | 1 site (Honolulu, United States) |
| Project start | August 1, 2017 |
| Project end | April 30, 2029 |
| Funding year | 2026 |
| Award (this year) | $273,873 |
| NIH project number | 5P20GM113134-08 |
| Project ID | NIH-11372089 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are adults with type 2 diabetes at risk for or with early signs of diabetic kidney disease, potentially eligible for future translational studies.
✕Less likely to help
People without diabetic kidney disease or those not affected by kidney inflammation may not directly benefit.
What this research studies
If you have type 2 diabetes and are at risk for kidney problems, this project looks at why inflammation and cellular waste management fail in the kidneys. Researchers will study kidney cells under high blood sugar to see how the non-canonical NF-kB signaling pathway interacts with autophagy. They will test what happens when a key receptor (Fn14) is removed in mice to see if kidney inflammation can be reduced, and they will explore potential inhibitors that could prevent disease progression. The work focuses on mechanisms that could lead to new ways to slow or stop kidney damage in diabetes.
Why it matters
Potential benefit: If successful, results could lead to new treatments that reduce kidney inflammation and slow DKD progression for people with type 2 diabetes.
How similar studies have gone: Previous studies have linked inflammatory pathways to kidney damage, but this project aims to uncover specific mechanisms and test targeted interventions.
Where this research is happening
-
University of Hawaii at Manoa
Honolulu, United States Active
Researchers
- Principal investigator: Ortega, Michael a. — University of Hawaii at Manoa
- Study coordinator: Ortega, Michael a.
Related research
Other NIH-funded projects on the same topics.
-
siRNA nanoparticle treatment to stop diabetic kidney damage
A new nanoparticle-delivered gene-silencing treatment aims to lower kidney inflammation in people with diabetes to help protect their kidneys.
-
LRG1’s role in diabetic kidney disease and kidney fibrosis
A study examines how a specific protein, LRG1, influences kidney disease related to diabetes and its scarring, with the aim of finding targeted ways to slow or prevent damage.
-
Genetic discovery for diabetic kidney disease in adults
A scientist team is studying the genes that influence diabetic kidney disease in adults to better understand why some people develop it.
-
Epidermal microfluidic screen to detect diabetic kidney disease
A new skin-based microfluidic test platform may help identify kidney complications in people with diabetes using real-time biomarkers from sweat and glucose data.
-
PFAS exposure and kidney disease risk in teens with type 2 diabetes
Aging and kidney health study in youths with type 2 diabetes to see how a common chemical (PFAS) affects kidney risk and how to prevent or treat it.
-
GSK3beta’s role in diabetic kidney disease and protecting kidney cells
This grant looks at how a molecule called GSK3beta affects kidney damage in people with diabetes and whether targeting it can protect kidney cells.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.